SCHOLAR ROCK HOLDING CORPORATION Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months
SCHOLAR ROCK HOLDING CORPORATION (SRRK) had Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months of $51.00 million as of 2025-03-31, per its 10-Q filed 2025-05-14.
Financial Statements › Notes › Debt and Equity Securities
us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months · last filed 2025-05-14
- 2025-03-31: Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months $51.00M.
- 2024-12-31: Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months $23.90M.
- 2024-09-30: Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months $0.00.
- 2024-06-30: Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months $81.30M.
| Period end | Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months |
|---|---|
| 2025-03-31 | $51.00M 10-Q · filed 2025-05-14 |
| 2024-12-31 | $23.90M 10-Q · filed 2025-05-14 |
| 2024-09-30 | $0.00 10-Q · filed 2024-11-12 |
| 2024-06-30 | $81.30M 10-Q · filed 2024-08-08 |
| 2024-03-31 | $113.20M 10-Q · filed 2024-05-07 |
| 2023-12-31 | $11.90M 10-K · filed 2025-02-27 |
| 2023-09-30 | $98.20M 10-Q · filed 2023-11-07 |
| 2023-06-30 | $85.00M 10-Q · filed 2023-08-09 |
| 2023-03-31 | $114.00M 10-Q · filed 2023-05-09 |
| 2022-12-31 | $212.10M 10-K · filed 2024-03-19 |
| 2022-09-30 | $211.50M 10-Q · filed 2022-11-14 |
| 2022-06-30 | $65.00M 10-Q · filed 2022-08-08 |
| 2022-03-31 | $105.20M 10-Q · filed 2022-05-16 |
| 2021-12-31 | $30.20M 10-K · filed 2023-03-07 |
| 2020-12-31 | $45.70M 10-K · filed 2022-03-07 |
| 2019-12-31 | $19.60M 10-K · filed 2021-03-09 |
| 2018-12-31 | $60.60M 10-K · filed 2020-03-12 |
| 2017-12-31 | $1.50M 10-K · filed 2019-03-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 | |
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | United States | $4.897B | -6.51 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |